Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes

The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently reduces heart failure (HF) hospitalization and cardiovascular death in type 2 diabetes (T2D). Empagliflozin-cardioprotection likely includes anti-inflammatory effects, regardless glucose lowering, but t...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannattasio, Silvia, Citarella, Anna, Trocchianesi, Sofia, Filardi, Tiziana, Morano, Susanna, Lenzi, Andrea, Ferretti, Elisabetta, Crescioli, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194473/
https://www.ncbi.nlm.nih.gov/pubmed/35712355
http://dx.doi.org/10.3389/fmolb.2022.879522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194473/
https://www.ncbi.nlm.nih.gov/pubmed/35712355
http://dx.doi.org/10.3389/fmolb.2022.879522

Ejemplares similares